Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine strategy versus premixed insulin strategy in type 2 diabetes
2009-018172-33Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin glargine, insulin aspart and insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Composite glycemic control without hypoglycemia. Started May 2010; status: completed.
02
Drugs
insulin glargineinsulin aspartinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-018172-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018172-33.